Asia Pacific Radiopharmaceuticals Market Analysis By Product (Diagnostics: SPECT, PET; Therapeutics: Alpha Emitters, Beta Emitters, Brachytherapy), By Type (Catheter, Doppler OCT, Handheld, Tabletop), By Application (Diagnostics: Cardiology, Neurology, Oncology, Thyroid, Lymphoma; Therapeutics: Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumor) And Segment Forecasts to 2024

1. Follow Us:
Asia Pacific Radiopharmaceuticals Market Analysis, Size,
Growth, Share & Forecast to 2024 | Grand View Research Inc.
The APAC Radiopharmaceuticals/Nuclear Medicine Market is expected to reach USD 2.9 billion by 2024,
according to the new report by Grand View Research, Inc. Radiopharmaceuticals are widely used in the field of
oncology, and cardiovascular diseases. Ongoing research and studies demonstrating positive results is
widening the scope of radioisotope applications for the diagnosis and treatment of bone diseases, respiratory
diseases, thyroid-related diseases, and conditions of the digestive tract. Along with these applications, the
radioisotopes are largely used in radiopharmacology to study drug movement in lab subjects.
Gamma emitter Technetium-99m is the most commonly used radioisotope in radiopharmaceuticals. Other
widely used radioisotopes include Fluorine-18, Indium-111, and Iodine-131. Numerous research studies are
further expanding the application areas of radiopharmaceuticals in diagnostics as well as in therapeutics.
Adoption of PET as a diagnostic tool is rapidly increasing since it offers high accuracy over other diagnostic
techniques. The accuracy in the diagnosis has a direct impact on decision-making and treatment monitoring
process. PET is commonly integrated with X-ray and computed tomography to increase the accuracy. The
growing demand for these diagnostic procedures is expected to fuel the market growth during the forecast
period.
Currently available cancer treatment options, such as chemotherapy and radiation therapy, include drugs and
radiations, which are non-target specific. Thus, these therapies have a major disadvantage of affecting the
whole body or the organs surrounding the target site. Radioisotopes have an advantage over these techniques
since they aid in targeting specifically the tumor without affecting the surrounding body parts. Thus, benefits
associated with these diagnostic and treatment procedures is augmenting the demand for
radiopharmaceuticals in disease treatment and diagnosis.
“Asia Pacific Radiopharmaceuticals Market to Reach $2.9 Billion By 2024”

2. Follow Us:
Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/asia-pacific-
radiopharmaceuticals-market
Further key findings from the study suggest:
• The buyers of radiopharmaceutical include hospitals, physicians, diagnostic laboratories, research
institutes and others. Hospitals form the biggest buyer groups owing to their high patient turnover and
greater financing capabilities.
• Therapeutic products such as Alpha Emitters, Beta Emitters and Brachytherapy are anticipated to
exhibit lucrative growth. Emergence of new treatment options for thyroid and other diseases is
expected to support the growth over the forecast period.
• The key diagnostic application areas of radiopharmaceuticals formed the largest market in 2015. These
applications are in cardiology, neurology, oncology, and thyroid. Advent of accurate diagnostic methods
and high burden of disorders supported the growth of this segment.
• Thailand in South East Asia and China are expected to dominate the APAC radiopharmaceutical
market. Efforts undertaken by the UN and other local healthcare authorities in this region are expected
to result in installation of more PET and SPECT systems, thereby driving the demand.
• Key players of the industry include Nordion, Inc., Bayer AG, Mallinckrodt Public Limited company, GE
Healthcare, Bracco Imaging S.P.A and government initiatives such as Institute of Radioisotopes and
The Australian Nuclear Science and Technology Organization (ANSTO)
Grand View Research has segmented the APAC radiopharmaceuticals market on the basis of product:
APAC Radiopharmaceuticals Product Outlook (Revenue, USD Million, 2013 - 2024)
• Diagnostics
o SPECT
o TC-99m
o TL-201
o GA-67
o I-123
o Others
o PET
o F-18
o RB-82
o Others

3. Follow Us:
• Therapeutics
o Alpha Emitters
o RA-223
o Beta Emitters
o I-131
o Y-90
o SM-153
o Re-186
o Lu-117
o Others
o Brachytherapy
o Cesium-131
o Iodine-125
o Palladium-103
o Iridium-192
o Others
Radiopharmaceuticals Regional Outlook (Revenue, USD Million, 2013 - 2024)
• South East Asia
o Indonesia
o Thailand
o Laos
o Myanmar
o Philippines
o Malaysia
o Vietnam
o Cambodia

4. Follow Us:
• Rest of Asia Pacific
o Japan
o China
o India
Table of Content
Chapter 1 Research Methodology
1.1 Information procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
4.1 Market segmentation & scope
4.1.1 Market Driver Analysis
4.1.1.1 Rising incidence of cancer and cardiovascular disease
4.1.1.2 Widening applications of radiopharmaceuticals
4.1.1.3 Growing demand for the accurate diagnostic methods
4.1.2 Market Restraint Analysis
4.1.2.1 Stringent regulation for production, storage, and usage
4.1.2.2 High costs involved in the procedure
4.2 Radiopharmecuticals - PESTLE Analysis
4.3 Industry Analysis - Porter’s
4.4 Penetration Index
4.5 Radiopharmaceuticals: Buyer profile
4.6 List of suppliers
4.7 Average Selling Price
Chapter 5 Market Categorization 1: Product Estimates & Trend Analysis
5.1 Radiopharmaceuticals market: Product movement analysis
5.2 Diagnostic products
5.2.1 Diagnostic products market, 2013 - 2024 (USD Million)
5.2.2 SPECT
5.2.2.1 SPECT products market, 2013 - 2024 (USD Million)

5. Follow Us:
5.2.3 TC-99m
5.2.3.1 TC-99m market, 2013 - 2024 (USD Million)
5.2.3.2 TL-201
5.2.3.3 TL-201 market, 2013 - 2024 (USD Million)
5.2.3.4 GA-67
5.2.3.5 GA-67 market, 2013 - 2024 (USD Million)
5.2.3.6 I-123
5.2.3.6.1 I-123 market, 2013 - 2024 (USD Million)
5.2.3.7 Other SPECT products
5.2.3.8 Other SPECT products market, 2013 - 2024 (USD Million)
5.2.4 PET
5.2.4.1 PET products market, 2013 - 2024 (USD Million)
5.2.4.2 F-18
5.2.4.2.1 F-18 market, 2013 - 2024 (USD Million)
5.2.4.3 RB-82
5.2.4.4 RB-82 market, 2013 - 2024 (USD Million)
5.2.4.5 Other PET products
5.2.4.5.1 Other PET products market, 2013 - 2024 (USD Million)
5.3 Therapeutic products
5.3.1 Therapeutic products market, 2013 - 2024 (USD Million)
5.3.2 Alpha emitters
5.3.2.1 Alpha emitters market, 2013 - 2024 (USD Million)
5.3.2.2 RA-223
5.3.2.2.1 RA-223 market, 2013 - 2024 (USD Million)
5.3.2.3 Other alpha emitters
5.3.2.3.1 Other alpha emitters market, 2013 - 2024 (USD Million)
5.3.3 Beta emitters
5.3.3.1 Beta emitters market, 2013 - 2024 (USD Million)
5.3.3.2 I-131
5.3.3.2.1 I-131 market, 2013 - 2024 (USD Million)
5.3.3.3 Y-90
5.3.3.3.1 Y-90 market, 2013 - 2024 (USD Million)
5.3.3.4 SM-153
5.3.3.4.1 SM-153 market, 2013 - 2024 (USD Million)

6. Follow Us:
5.3.3.5 Re-186
5.3.3.5.1 Re-186 market, 2013 - 2024 (USD Million)
5.3.3.6 Lu-117
5.3.3.6.1 Lu-117 market, 2013 - 2024 (USD Million)
5.3.3.7 Other beta emitters
5.3.3.7.1 Other beta emitters market, 2013 - 2024 (USD Million)
5.3.4 Brachytherapy
5.3.4.1 Brachytherapy market, 2013 - 2024 (USD Million)
5.3.4.2 Cesium-131
5.3.4.2.1 Cesium-131 market, 2013 - 2024 (USD Million)
5.3.4.3 Iodine-125
5.3.4.3.1 Iodine-125 market, 2013 - 2024 (USD Million)
5.3.4.4 Palladium-103
5.3.4.4.1 Palladium-103 market, 2013 - 2024 (USD Million)
5.3.4.5 Iridium-192
5.3.4.6 Iridium-192 market, 2013 - 2024 (USD Million)
5.3.4.7 Other brachytherapy products
5.3.4.7.1 Other brachytherapy products market, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Application Estimates & Trend Analysis
6.1 Radiopharmaceuticals market: Application movement analysis
6.2 Diagnostic application
6.2.1 Diagnostic application market, 2013 - 2024 (USD Million)
6.2.2 Cardiology
6.2.2.1 Cardiology applications market, 2013 - 2024 (USD Million)
6.2.3 Neurology
6.2.3.1 Neurology applications market, 2013 - 2024 (USD Million)
6.2.4 Oncology
6.2.4.1 Oncology applications market, 2013 - 2024 (USD Million)
6.2.5 Thyroid
6.2.5.1 Thyroid applications market, 2013 - 2024 (USD Million)
6.2.6 Lymphoma
6.2.6.1 Lymphoma applications market, 2013 - 2024 (USD Million)
6.2.7 Other diagnostic application
6.2.7.1 Other diagnostic applications market, 2013 - 2024 (USD Million)

7. Follow Us:
6.3 Therapeutic application
6.3.1. Therapeutic application market, 2013 - 2024 (USD Million)
6.3.2 Thyroid
6.3.2.1 Thyroid applications market, 2013 - 2024 (USD Million)
6.3.3 Bone metastasis
6.3.4 Bone metastasis applications market, 2013 - 2024 (USD Million)
6.3.5 Lymphoma
6.3.5.1 Lymphoma applications market, 2013 - 2024 (USD Million)
6.3.6 Endocrine tumor
6.3.6.1 Endocrine tumor market, 2013 - 2024 (USD Million)
6.3.7 Other therapeutic application
6.3.7.1 Other therapeutic applications market, 2013 - 2024 (USD Million)
Chapter 7 Market Categorization 3: Regional Estimates & Trend Analysis, by Product and Applications
7.1 Asia Pacific Radiopharmaceuticals market share by region, 2015 & 2024
7.2 Southeast Asia
7.2.1 Southeast Asia radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.2.2 Indonesia
7.2.2.1 Indonesia radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.2.3 Thailand
7.2.3.1 Thailand radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.2.4 Laos
7.2.4.1 Laos radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.2.5 Myanmar
7.2.5.1 Myanmar radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.2.6 Philippines
7.2.6.1 Philippines radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.2.7 Malaysia
7.2.7.1 Malaysia radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.2.8 Vietnam
7.2.8.1 Vietnam radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.2.9 Cambodia
7.2.9.1 Cambodia radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.3 Rest of Asia Pacific
7.3.1 Rest of Asia Pacific radiopharmaceuticals market, 2013 - 2024 (USD Million)

8. Follow Us:
7.3.2 Japan
7.3.2.1 Japan radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.3.3 China
7.3.3.1 China radiopharmaceuticals market, 2013 - 2024 (USD Million)
7.3.4 India
7.3.4.1 India radiopharmaceuticals market, 2013 - 2024 (USD Million)
Chapter 8 Competitive Landscape
8.1 Bayer AG
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Mallinckrodt public limited company
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 GE Healthcare
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Jubilant Life Sciences
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Bracco Imaging S.p.A
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Nordion, Inc.
8.6.1 Company Overview

9. Follow Us:
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 The Institute for Radioelements (The IRE)
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 Australian Nuclear Science & Technology Organization (ANSTO)
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.9 NTP Radioisotopes SOC Ltd.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 Eczacibasi-Monrol
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives

10. Follow Us:
About Grand View Research, Inc.:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports,
customized research reports, and consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based research across a range of
industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com